首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1377390

阿片类药物使用障碍药物市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、给药途径、按地区和竞争的配销通路细分

Opioid Use Disorder Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Route of Administration, By Distribution Channel By Region and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2022 年，全球阿片类药物使用障碍药物市场价值为 24.5 亿美元，预计在预测期内将强劲增长，到 2028 年CAGR为7.65%。全球阿片类药物使用障碍药物市场是更广泛领域中一个动态且关键的领域。製药业，致力于解决全球范围内不断升级的鸦片类药物成瘾危机。随着阿片类药物滥用和与服用过量相关的死亡达到惊人的水平，该市场在提供有效解决方案来应对这一公共卫生危机方面发挥关键作用。阿片类药物使用疾患 (OUD) 药物涵盖一系列旨在治疗鸦片类药物成瘾的药物干预措施，包括处方止痛药和海洛因等非法物质。这些药物通常分为三类：鸦片激动剂、部分激动剂和拮抗剂，每种药物都有其独特的作用机转。该市场的主要药物包括美沙酮、丁丙诺啡、纳曲酮和纳洛酮，它们以多种形式给药，例如口服片剂、舌下膜剂或註射剂。

近年来，在多种因素的推动下，市场出现了显着成长。阿片类药物成瘾病例的激增、人们对阿片类药物流行病的认识提高以及政府加大扩大治疗范围的倡议都促进了市场的扩张。此外，正在进行的研究和开发工作旨在创造更安全、更有效的药物来解决 OUD，同时最大限度地减少副作用和滥用的可能性。市场动态也受到不断变化的监管环境和不断变化的报销政策的影响。全球 OUD 药物市场的特点是製药公司之间的竞争，这些公司努力创新并在这个快速成长的行业中占据份额。随着行业参与者寻求增强其产品组合和市场占有率，市场整合、合作伙伴关係和策略合作已变得司空见惯。

主要市场驱动因素

市场概况
预测期	2024-2028
2022 年市场规模	24.5亿美元
2028 年市场规模	37.9亿美元
2023-2028 年CAGR	7.65%
成长最快的细分市场	网路药局
最大的市场	北美洲

阿片类药物流行不断升级

商业概览
公司概况
产品与服务
财务（上市公司）
最近的发展
SWOT分析
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals Inc
- Collegium Pharmaceutical, Inc.
- Braeburn, Inc.
- Purdue Pharma LP
- Curia Global Inc.
- EMERGENT
- Bristol-Myers Squibb, Srl
- Alkermes, Inc.
- Indivior Inc.

策略建议

简介目录

Product Code: 16779

Global Opioid Use Disorder Drugs Market has valued at USD 2.45 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 7.65% through 2028. The Global Opioid Use Disorder Drugs Market is a dynamic and critical segment within the broader pharmaceutical industry, dedicated to addressing the escalating crisis of opioid addiction worldwide. With opioid abuse and overdose-related deaths reaching alarming levels, this market plays a pivotal role in providing effective solutions to combat this public health crisis. Opioid Use Disorder (OUD) drugs encompass a range of pharmaceutical interventions designed to treat addiction to opioids, including prescription painkillers and illicit substances like heroin. These medications typically fall into three categories: opioid agonists, partial agonists, and antagonists, each with its unique mechanism of action. Key drugs within this market include methadone, buprenorphine, naltrexone, and naloxone, which are administered in various forms such as oral tablets, sublingual films, or injectables.

The market has witnessed significant growth in recent years, driven by multiple factors. The surge in opioid addiction cases, heightened awareness of the opioid epidemic, and increased government initiatives to expand access to treatment have all contributed to market expansion. Additionally, ongoing research and development efforts aim to create safer and more effective drugs to address OUD while minimizing side effects and potential for abuse. Market dynamics are also influenced by evolving regulatory landscapes and changing reimbursement policies. The global OUD drugs market is marked by competition among pharmaceutical companies striving to innovate and capture a share of this rapidly growing sector. Market consolidation, partnerships, and strategic collaborations have become commonplace as industry players seek to bolster their product portfolios and market presence.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 2.45 Billion
Market Size 2028	USD 3.79 Billion
CAGR 2023-2028	7.65%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

Escalating Opioid Epidemic

The escalating opioid epidemic has played a pivotal role in boosting the Global Opioid Use Disorder (OUD) Drugs Market, reshaping the pharmaceutical landscape in response to one of the most pressing public health crises of our time. This crisis, characterized by the widespread misuse of prescription opioids and the proliferation of illicit opioids like heroin, has had devastating consequences, including an alarming increase in opioid-related deaths. As communities grapple with the devastating effects of addiction, the demand for effective treatments has surged. This heightened demand has created a fertile ground for pharmaceutical companies to develop, market, and distribute a range of OUD drugs. The opioid epidemic has unfolded on a global scale, transcending geographical and demographic boundaries. Consequently, governments, healthcare organizations, and the public have recognized the urgency of addressing this crisis comprehensively. This collective awareness has spurred significant investments in addiction treatment programs, policies aimed at expanding access to OUD drugs, and campaigns to reduce stigma surrounding addiction. Such concerted efforts have not only saved lives but have also contributed to the expansion of the OUD Drugs Market as more individuals seek help and treatment.

Furthermore, as healthcare professionals and policymakers grapple with the opioid crisis, the pharmaceutical industry has responded by developing innovative medications tailored to treat OUD effectively. These medications, falling into categories such as opioid agonists, partial agonists, and antagonists, have undergone continuous refinement to enhance their efficacy and safety profiles. Additionally, advancements like extended-release formulations have made treatment more convenient for patients.

Advancements in Treatment Options

Advancements in treatment options have been a significant driving force behind the remarkable growth of the Global Opioid Use Disorder (OUD) Drugs Market. As the opioid epidemic has continued to escalate, the pharmaceutical industry has responded with innovative and increasingly effective solutions to address the complexities of addiction treatment. One of the most notable advancements has been in the development of different classes of OUD medications, which provide diverse options for healthcare professionals and patients. These include opioid agonists, partial agonists, and antagonists, each designed to target specific aspects of opioid dependence. For example, methadone and buprenorphine, both opioid agonists, have been used successfully to reduce cravings and withdrawal symptoms. Partial agonists like Suboxone (buprenorphine/naloxone) offer a safer profile, minimizing the risk of overdose, while antagonists like naltrexone block the effects of opioids, serving as a deterrent against relapse.

In addition to diversified drug classes, innovations in drug delivery mechanisms have also transformed the OUD treatment landscape. Extended-release formulations, such as Sublocade (extended-release buprenorphine) and Probuphine (implantable buprenorphine rods), have gained prominence. These formulations offer the advantage of sustained symptom relief, reducing the need for daily medication administration. This not only improves patient adherence but also reduces the risk of diversion and misuse. Advancements in molecular pharmacology and neuroscience have deepened our understanding of the neurobiology of addiction. This knowledge has led to the development of more targeted and precise OUD medications. Researchers are exploring novel approaches, such as opioid receptor modulators and combination therapies, which hold the promise of increased effectiveness and fewer side effects.

Ongoing Research and Development

Pharmaceutical companies and academic institutions have invested significantly in research to better understand the neurobiology of addiction and the mechanisms underlying opioid dependence. This deepening understanding has led to the discovery of new drug targets and novel treatment approaches. Researchers are exploring innovative pharmacological agents and therapeutic strategies that aim to not only alleviate withdrawal symptoms and cravings but also address the psychological and behavioral aspects of addiction. One notable area of research has been the development of opioid receptor modulators, which can selectively target specific receptor subtypes, potentially minimizing side effects while optimizing therapeutic benefits. These targeted approaches offer the promise of more personalized treatment regimens, enhancing the overall effectiveness of OUD medications.

Combination therapies are also gaining traction in research and development. By combining different classes of OUD medications, researchers seek to leverage synergistic effects to improve treatment outcomes. This approach may enhance patient adherence and reduce the risk of relapse, marking a significant advancement in addiction treatment. Moreover, research is focusing on developing non-opioid alternatives for managing pain, as many individuals initially become addicted to opioids through prescription painkillers. The development of non-addictive pain management options has the potential to reduce the demand for opioids and, consequently, the prevalence of OUD. Additionally, research efforts are dedicated to improving drug delivery mechanisms. Scientists are exploring innovative formulations, such as implantable devices and long-acting injectables, to provide sustained symptom relief, minimize diversion, and enhance patient convenience.

Key Market Challenges

Regulatory Complexity

One of the primary challenges is the lack of uniformity in regulations across different regions and countries. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and counterparts in other nations, have unique guidelines and requirements for OUD medications. This variation can lead to confusion and increased compliance costs for pharmaceutical companies operating internationally. The opioid epidemic is a rapidly evolving crisis, and regulatory agencies often struggle to keep pace with emerging trends and challenges. This lag in adapting regulations can hinder the timely approval of new medications and treatment modalities, impeding the market's ability to respond effectively to the crisis.

OUD medications, including opioid agonists like methadone and buprenorphine, are subject to strict regulations surrounding their prescription and dispensing. Healthcare providers must undergo specialized training and obtain waivers to prescribe these medications, creating barriers to access. Furthermore, stringent record-keeping requirements and oversight can deter providers from offering these treatments. Some OUD medications are subject to Risk Evaluation and Mitigation Strategies, which impose additional requirements on manufacturers and healthcare providers. While these strategies are intended to enhance the safe use of medications, they can also increase the administrative burden and costs associated with bringing OUD drugs to market.

Cost of Medications

The development of OUD medications requires extensive research, clinical trials, and regulatory approvals, all of which incur substantial costs. Pharmaceutical companies invest heavily in these processes, and these expenses often translate into high drug prices once they reach the market. The OUD Drugs Market often features a limited number of manufacturers producing these specialized medications. The lack of competition allows companies to set higher prices without fear of price undercutting. Consequently, patients and healthcare systems have limited options, and the lack of market competition exacerbates the cost burden. Many OUD medications are protected by patents, granting manufacturers exclusive rights to produce and market these drugs.

While patents are essential for incentivizing research and development, they also allow manufacturers to maintain high prices for an extended period, limiting the availability of more affordable generic versions. Some OUD medications receive orphan drug designation, intended to promote the development of therapies for rare diseases. While this designation offers incentives such as extended exclusivity periods and tax credits, it can lead to substantially higher drug prices, impacting the affordability of these medications for patients.

Key Market Trends

Expansion of Medication-Assisted Treatment (MAT)

One of the most significant trends in the OUD Drugs Market is the increasing adoption of Medication-Assisted Treatment (MAT). MAT combines pharmacotherapy, such as opioid agonists (e.g., methadone and buprenorphine), with counseling and behavioral therapies to address opioid addiction comprehensively. MAT is now widely recognized as the gold standard of care for OUD, and its expansion has significantly boosted the market. Increased Access to Treatment: MAT programs have proliferated, making treatment more accessible to individuals grappling with OUD. The availability of MAT in a variety of healthcare settings, including specialized clinics, primary care offices, and even pharmacies, has broadened the reach of OUD treatment. MAT has demonstrated its effectiveness in reducing opioid misuse, promoting long-term recovery, and preventing opioid overdose deaths. As more individuals have access to MAT, better treatment outcomes become achievable, leading to increased confidence in these therapies.

MAT has played a pivotal role in reducing the stigma associated with OUD treatment. By emphasizing the medical aspect of addiction, MAT has helped change societal attitudes, making it more acceptable for individuals to seek help for their addiction without fear of judgment or discrimination. Governments and healthcare authorities have recognized the value of MAT in addressing the opioid epidemic. They have implemented policies and initiatives aimed at expanding access to MAT, providing financial support, and reducing administrative barriers, which in turn has encouraged market growth. The surge in demand for MAT has sparked innovation in the development of new OUD medications and improved formulations. Researchers are constantly exploring ways to enhance the safety and efficacy of MAT drugs, which stimulates further growth in the OUD Drugs Market.

Telehealth and Digital Solutions

Increased Access to Treatment: Telehealth has expanded the reach of addiction treatment by enabling patients to connect with healthcare professionals from the comfort of their homes. This newfound accessibility is especially vital for individuals residing in rural or underserved areas with limited access to addiction treatment facilities. Telehealth has improved the continuity of care for individuals in OUD treatment programs. Patients can maintain regular contact with healthcare providers, ensuring consistent medication management and support, which is crucial for recovery.Telehealth facilitates remote counseling and support services, which are integral components of addiction treatment. Patients can participate in individual and group therapy sessions virtually, reducing barriers to consistent engagement in counseling.

Telehealth platforms allow healthcare providers to monitor patients' progress, adjust medication regimens, and address any concerns promptly. This remote oversight enhances patient safety and adherence to OUD medications. Telehealth affords individuals seeking OUD treatment a degree of privacy that might not be achievable in traditional in-person settings. This reduction in stigma encourages more individuals to seek help and engage in treatment.Digital solutions, including smartphone apps and web-based platforms, provide additional support for individuals in recovery. These tools can offer medication reminders, coping strategies, and resources to help patients manage their OUD more effectively.

Segmental Insights

Drug Type Insights

Based on the drug Type, the agonist drugs segment emerged as the dominant player in the global market for Global Opioid Use Disorder Drugs Market in 2022. This is on account of their ability to effectively address opioid addiction by targeting the same receptors in the brain that opioids do, thereby reducing cravings and withdrawal symptoms.

Route of Administration Insights

Based on the Route of Administration, the Oral segment emerged as the dominant player in the global market for Global Opioid Use Disorder Drugs Market in 2022. Oral medications are generally easy to administer and do not require specialized medical procedures or equipment. Patients can take their medication at home or in a clinical setting, enhancing convenience and accessibility.

Regional Insights

North America emerged as the dominant player in the global Opioid Use Disorder Drugs Market in 2022, holding the largest market share. North America has been at the forefront of promoting Medication-Assisted Treatment for OUD. The availability and integration of MAT programs in addiction treatment have been substantial, ensuring that patients have access to evidence-based care.

Key Market Players

Mallinckrodt Pharmaceuticals

Hikma Pharmaceuticals Inc

Collegium Pharmaceutical, Inc.

Braeburn, Inc.

Purdue Pharma L.P.

Curia Global Inc.

EMERGENT

Bristol-Myers Squibb, S.r.l

Alkermes, Inc.

Indivior Inc.

Report Scope:

In this report, the Global Opioid Use Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Opioid Use Disorder Drugs Market, By Drug Type:

Agonist Drugs
Antagonist Drugs
Others

Global Opioid Use Disorder Drugs Market, By Route of Administration:

Oral
Parenteral
Sublingual
Nasal

Global Opioid Use Disorder Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Opioid Use Disorder Drugs Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Turkey
Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Opioid Use Disorder Drugs Market.

Available Customizations:

Global Opioid Use Disorder Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Opioid Use Disorder Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Agonist Drugs, Antagonist Drugs, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral, Sublingual, Nasal)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Company (2022)
- 5.2.5. By Region
5.3. Market Map

6. North America Opioid Use Disorder Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Opioid Use Disorder Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Mexico Opioid Use Disorder Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Canada Opioid Use Disorder Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Distribution Channel

7. Europe Opioid Use Disorder Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Opioid Use Disorder Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. Germany Opioid Use Disorder Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Opioid Use Disorder Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Opioid Use Disorder Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Opioid Use Disorder Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Opioid Use Disorder Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Opioid Use Disorder Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Opioid Use Disorder Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. South Korea Opioid Use Disorder Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. Japan Opioid Use Disorder Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Opioid Use Disorder Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

9. South America Opioid Use Disorder Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Opioid Use Disorder Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Opioid Use Disorder Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Opioid Use Disorder Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Opioid Use Disorder Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Opioid Use Disorder Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Opioid Use Disorder Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Opioid Use Disorder Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
- 15.6.1. Mallinckrodt Pharmaceuticals
- 15.6.2. Hikma Pharmaceuticals Inc
- 15.6.3. Collegium Pharmaceutical, Inc.
- 15.6.4. Braeburn, Inc.
- 15.6.5. Purdue Pharma L.P.
- 15.6.6. Curia Global Inc.
- 15.6.7. EMERGENT
- 15.6.8. Bristol-Myers Squibb, S.r.l
- 15.6.9. Alkermes, Inc.
- 15.6.10. Indivior Inc.